Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBITDA (2019 - 2025)

Historic EBITDA for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$41.1 million.

  • Allogene Therapeutics' EBITDA rose 3708.31% to -$41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$211.9 million, marking a year-over-year increase of 2454.03%. This contributed to the annual value of -$256.7 million for FY2024, which is 1934.38% up from last year.
  • Per Allogene Therapeutics' latest filing, its EBITDA stood at -$41.1 million for Q3 2025, which was up 3708.31% from -$51.0 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' EBITDA peaked at -$2.1 million during Q4 2021, and registered a low of -$96.0 million during Q1 2023.
  • For the 5-year period, Allogene Therapeutics' EBITDA averaged around -$66.3 million, with its median value being -$66.2 million (2024).
  • Per our database at Business Quant, Allogene Therapeutics' EBITDA surged by 9846.18% in 2021 and then plummeted by 442438.79% in 2022.
  • Allogene Therapeutics' EBITDA (Quarter) stood at -$2.1 million in 2021, then tumbled by 4424.39% to -$94.2 million in 2022, then rose by 10.53% to -$84.3 million in 2023, then grew by 28.62% to -$60.2 million in 2024, then soared by 31.68% to -$41.1 million in 2025.
  • Its EBITDA was -$41.1 million in Q3 2025, compared to -$51.0 million in Q2 2025 and -$59.6 million in Q1 2025.